Calviri: Funding, Investors & Team (Sep 2026)
Calviri provides cancer treatment products by combining the immunogenic source of neoantigens with a peptide array platform. On its course to eradicate cancer it develops new diagnostic and therapeutic products, and then preventative vaccines that will stop cancer from starting. The company's approach can provide both cancer diagnostics and vaccines. It is based on the discovery of an unrecognized source of frameshift neoantigens. These immunogenic peptides are generated from very frequent errors in tumor-cell RNA synthesis and processing. They provide both cancer-specific and shared frameshift neoantigens for a new class of diagnostic and vaccine products. Calviri was founded in 2018 and is headquartered in Tempe, Arizona.
Calviri has raised $8.3M across 3 funding rounds on record, the most recent an undisclosed round of $790k announced in Nov 2024.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Calviri Company Profile and Key Stats
Latest funding round on record: Nov 2024.
Calviri Funding Rounds
Calviri raised $2.3M in an undisclosed round announced in Apr 2020.
1.6 years later, an undisclosed round of $5.2M was announced in Nov 2021.
3 years later, an undisclosed round of $790k was announced in Nov 2024.
Calviri Founders and Leadership Team
Contact details for the Calviri team: 1 of 1 has an email address on file.
Start 14-day free trial →Calviri Funding Compared to Other Biotechnology Startups
Calviri's latest round of $790k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Calviri in Biotechnology and Tempe
Companies Similar to Calviri
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Calviri Funding FAQs
What does Calviri do?
Calviri provides cancer treatment products by combining the immunogenic source of neoantigens with a peptide array platform. On its course to eradicate cancer it develops new diagnostic and therapeutic products, and then preventative vaccines that will stop cancer from starting. The company's approach can provide both cancer diagnostics and vaccines. It is based on the discovery of an unrecognized source of frameshift neoantigens. These immunogenic peptides are generated from very frequent errors in tumor-cell RNA synthesis and processing. They provide both cancer-specific and shared frameshift neoantigens for a new class of diagnostic and vaccine products. Calviri was founded in 2018 and is headquartered in Tempe, Arizona.
How much funding has Calviri raised?
Calviri has raised $8.3M across 3 rounds on record. The most recent is an undisclosed round of $790k announced in Nov 2024.
When did Calviri last raise funding?
Calviri's most recent funding round on record is an undisclosed round of $790k, announced in Nov 2024.
Who is the CEO of Calviri?
Stephen Albert Johnston is listed as CEO at Calviri.
Where is Calviri headquartered?
Calviri is based in Tempe, Arizona, United States.
How many employees does Calviri have?
Calviri is in the 1-10 employee band.
How does Calviri's funding compare to other Biotechnology startups?
Calviri's latest round of $790k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Calviri Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Calviri is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.